Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as well as in combination with immunomodulatory drugs (IMiDs) and proteasome inh...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Ghose, Jayeeta, Viola, Domenico, Terrazas, Cesar, Caserta, Enrico, Troadec, Estelle, Khalife, Jihane, Gunes, Emine Gulsen, Sanchez, James, McDonald, Tinisha, Marcucci, Guido, Kaur, Balveen, Rosenzweig, Michael, Keats, Jonathan, Rosen, Steven, Krishnan, Amrita, Satoskar, Abhay R, Hofmeister, Craig C, Pichiorri, Flavia
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6169590/
https://ncbi.nlm.nih.gov/pubmed/30288349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1486948
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires